Once-daily triple-Tx improves lung function, HRQoL in COPD

August 22, 2017

(HealthDay)—For patients with chronic obstructive pulmonary disease (COPD), once-daily single-inhaler triple therapy is better for lung function and health-related quality of life than inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA) therapy, according to a study published in the Aug. 15 issue of the American Journal of Respiratory and Critical Care Medicine.

David A. Lipson, M.D., from GlaxoSmithKline in King of Prussia, Pa., and colleagues compared the effects of once-daily triple on and health-related quality of life with twice-daily ICS/LABA therapy for 24 weeks as part of a randomized trial. A total of 1,810 participants were randomized to triple therapy (911 patients; fluticasone furoate/umeclidinium/vilanterol) and ICS/LABA therapy (899 patients; budesonide/formoterol). A subgroup of patients remained on blinded treatment for up to 52 weeks.

The researchers found that the mean changes from baseline in forced expiratory volume in one second were 142 mL and −29 mL, for the triple therapy and ICS/LABA therapy groups, respectively; mean changes from baseline in St. George's Respiratory Questionnaire scores were −6.6 and −4.3 units, respectively. The between-group differences for both end points were statistically significant. For triple therapy versus dual ICS/LABA therapy there was a statistically significant reduction in moderate/severe exacerbation rates (35 percent reduction).

"These results support the benefits of single-inhaler triple therapy compared with ICS/LABA therapy in patients with advanced COPD," the authors write.

Several authors disclosed financial ties to GlaxoSmithKline, which funded the study.

Explore further: Triple therapy no benefit for COPD exacerbations

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Triple therapy no benefit for COPD exacerbations

April 26, 2016
(HealthDay)—The addition of tiotropium to long-acting β2-agonists (LABA) and/or inhaled corticosteroids (ICS) does not reduce chronic obstructive pulmonary disease (COPD) exacerbations compared to LABA/ICS alone, according ...

Trial of new triple inhaler shows 20 percent reduction in COPD flare-ups

April 3, 2017
Flare-ups in chronic obstructive pulmonary disease, the UK's fourth leading cause of death, can be reduced by 20% by a combined triple inhaler, according to the results of a trial of more than 2,000 people conducted by The ...

Fluticasone furoate slows loss of lung function in COPD

August 4, 2017
(HealthDay)—Regular use of fluticasone furoate (FF), either alone or in combination with vilanterol (VI), appears to reduce the rate of forced expiratory volume in one second (FEV1) decline in patients with moderate chronic ...

Most patients prefer oral dual therapy in chronic hepatitis C

September 20, 2016
(HealthDay)—For patients with chronic hepatitis C (CHC), most prefer oral therapy with sofosbuvir (SOF) and ribavirin (RBV) versus triple therapy involving pegylated interferon (PegIFN), according to a study published online ...

ATS: Indacaterol-glycopyrronium cuts COPD exacerbations

May 16, 2016
(HealthDay)—For patients with a history of chronic obstructive pulmonary disease (COPD) exacerbations, indacaterol-glycopyrronium is more effective for prevention of exacerbations than salmeterol-fluticasone, according ...

Recommended for you

Gut bacteria markers could be a 'smoking gun' for liver disease

June 25, 2018
Chemical compounds produced by the bacteria in our gut could be used to spot the early stages of liver disease, according to new research.

Cholera spread tracked at household level

June 25, 2018
For the first time, the transmission of cholera has been tracked at the household level across Dhaka, Bangladesh, a city with a 'hyper-endemic' level of the disease. Researchers from the Wellcome Sanger Institute and their ...

Discovery of kidney structure challenges current understanding of renal physiology

June 25, 2018
New research by the University of Bristol has found that the microscopic structure of human kidney is different to what was previously known.

Lipid-based nanoparticles enable improved therapy for cystic fibrosis patients

June 25, 2018
Researchers at Oregon State University and Oregon Health & Science University are working on a treatment that holds great promise for improving the lives of cystic fibrosis patients.

Study identifies gene expression patterns associated with fatty liver disease

June 25, 2018
A fatty liver disease known as NASH—non-alcoholic steatohepatitis—is the nation's major cause of chronic liver disease, and is projected to become the most common indicator for liver transplants.

Non-invasive malaria test wins Africa engineering prize

June 24, 2018
Languishing with fever and frustrated by delays in diagnosing his illness, Brian Gitta came up with a bright idea: a malaria test that would not need blood samples or specialized laboratory technicians.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.